Surrozen is a small biotech developing novel and complex bispecific antibodies that target activation of the WNT pathway to take advantage of its regenerative potential. Although the WNT pathway has been studied for decades, Surrozen is aiming to develop the first therapeutics that intervene in this pathway, and only in diseased tissue.
While still working on antibody engineering work, Surrozen was keen to get started quickly on process development and manufacturing, and knew that it needed a CDMO with experience developing and producing bispecific antibodies and fusion proteins. This led to engagement with Lonza, who showed great appetite for the novel science and embarked on two programs at the same time. Lonza’s scientists worked seamlessly with the California-based biotech to advance the challenging molecules to the point of being in the clinic in 2022.
Learn more about Surrozen’s experience with Lonza from its President & CEO, Craig Parker.